# ENJAYMO
> **BLA761164** · Biologics License Application · Sponsor: RECORDATI RARE DISEASES, INC. · Approved 2022-02-04
## Drug
- **FDA Application Number:** BLA761164
- **Application type:** Biologics License Application
- **Brand name:** ENJAYMO
- **Generic name:** SUTIMLIMAB-JOME
- **Active ingredients:** SUTIMLIMAB-JOME
- **Dosage form:** INJECTABLE
- **Route:** INJECTION
- **Marketing status:** Prescription
- **Sponsor:** RECORDATI RARE DISEASES, INC.
- **Manufacturer:** Recordati Rare Diseases, Inc.
- **First approval:** 2022-02-04
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761164)
---
*AI Analytics · CC0 1.0*